BRIEF-Qxo Inc Reaffirms Commitment To Acquiring Beacon For $124.25 Per Share In Cash-February 2024-www.financetom.com

BRIEF-Qxo Inc Reaffirms Commitment To Acquiring Beacon For $124.25 Per Share In Cash

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Qxo Inc Reaffirms Commitment To Acquiring Beacon For $124.25 Per Share In Cash

Jan 28, 2025 5:48 AM

Jan 28 (Reuters) - QXO Inc ( QXO ):

* QXO COMMENTS ON BEACON ROOFING SUPPLY'S ADOPTION OF

SHAREHOLDER-UNFRIENDLY POISON PILL

* QXO INC ( QXO ): REAFFIRMS COMMITMENT TO ACQUIRING BEACON FOR

$124.25

PER SHARE IN CASH

* QXO INC ( QXO ) - QXO'S TENDER OFFER WILL BE OUTSTANDING UNTIL

12:00

MIDNIGHT, NEW YORK CITY TIME, AT END OF FEB 24, 2025

Source text:

Further company coverage:

;))

Previous page： Walmart Canada to invest more than $4 billion to expand stores, supply chain Next page： Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Walmart Canada to invest more than $4 billion to expand stores, supply chain

Jan 30, 2025

(Reuters) - Walmart Canada said on Thursday it is investing about C$6.5 billion ($4.51 billion) to build new stores and expand its supply chain, marking its biggest ever investment since opening its first store nearly 30 years ago. U.S. retail giant Walmart's Canadian branch, which plans to expand its footprint, added it would be building dozens of new stores starting...

Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced

Jan 30, 2025

10:45 AM EST, 01/30/2025 (MT Newswires) -- Kazia Therapeutics' ( KZIA ) shares jumped 55% in recent Thursday trading after the company announced the regulatory approval and launch of a clinical trial evaluating the combination of its investigational drug paxalisib and immunotherapy in patients with advanced breast cancer. The multi-center, open-label phase 1b study will assess the safety and efficacy...

Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program

Jan 30, 2025

10:44 AM EST, 01/30/2025 (MT Newswires) -- Guardant Health ( GH ) said Thursday it signed an agreement with the Abu Dhabi Public Health Center to launch a blood-based colorectal cancer screening using the Shield test. Hikma Pharmaceuticals, a regional partner for Guardant in the Middle East and North Africa, arranged the deal, which will be implemented by the M42...

iHeartMedia Signs Deal to Become Sales Partner for BBC Podcasts in US

Jan 30, 2025

10:46 AM EST, 01/30/2025 (MT Newswires) -- iHeartMedia (IHRT) and BBC Studios said Thursday that they have signed a multi-year deal under which iHeartMedia will become the third-party advertising reseller of the British broadcaster's podcasts in the US. Financial details of the deal were not provided. ...